SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in ...
In the study cohort, 2,310 patients died during a median follow-up of 6.3 years, and prostate cancer accounted for 454 (19.7% ...
Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...
SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in ...
A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...
The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...
The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching ...
Japanese scientists, examining data from 20,000 people, found that men with low libido had a much higher risk of serious ...
Being diagnosed with prostate cancer is not a death knell,” said Montgomery, senior author of a literature and trial review that appeared in JAMA today. Montgomery is the clinical director of ...
Dear Dr. Roach: I am 90 years old. About 20 years ago, I had prostate cancer and went through 43 weeks of radiation. My PSA level in the past year has risen slightly from .03 ng/mL to .09 ng/mL. My ...
A 66-year-old male patient underwent surgery for prostate cancer 4 years ago. His initial prostate-specific antigen (PSA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback